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Abstract: Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. Effective treatment of 
HCC patients is hampered by the lack of sensitive and speciﬁ  c diagnostic markers of HCC. Alpha-fetoprotein (AFP), the 
currently used HCC marker, misses 30%–50% of HCC patients, who therefore remain undiagnosed and untreated. In order 
to identify novel diagnostic markers that can be used individually or in combination with AFP, we used an antibody array 
platform to detect the levels of candidate proteins in the plasma of HCC patients (n = 48) and patients with chronic hepati-
tis B or C viral infections (n = 19) (both of which are the major risk factors of HCC). We identiﬁ  ed 7 proteins that signiﬁ  cantly 
differentiate HCC patients from hepatitis patients (p   0.05) (AFP, CTNNB, CSF1, SELL, IGFBP6, IL6R, and VCAM1). 
Importantly, we also identiﬁ  ed 8 proteins that signiﬁ  cantly differentiate HCC patients with ‘normal’ levels of AFP ( 20 ng/ml) 
from hepatitis patients (p   0.05) (IL1RN, IFNG, CDKN1A, RETN, CXCL14, CTNNB, FGF2, and SELL). These markers 
are potentially important complementary markers to AFP. Using an independent immunoassay method in an independent 
group of 23 HCC patients and 22 hepatitis patients, we validated that plasma levels of CTNNB were signiﬁ  cantly higher in 
the HCC group (p = 0.020). In conclusion, we used an antibody array platform to identify potential circulating diagnostic 
markers of HCC, some of which may be valuable when used in combination with AFP. The clinical utility of these newly 
identiﬁ  ed HCC diagnostic markers needs to be systematically evaluated.
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Introduction
Biomarker discovery is a burgeoning area of cancer research which encompasses the search for new 
diagnostic, prognostic, and treatment response markers of cancers. The ability to ﬁ  nd new diagnostic 
markers of early stage cancers in particular holds great promise for more efﬁ  cacious management of 
cancers that are hard-to-treat and that have poor patient survival, such as hepatocellular carcinoma 
(HCC). HCC is the third leading cause of cancer deaths worldwide (1). Its high mortality is in part due 
to limitations in early diagnosis of the malignancy. Patients often do not have overt symptoms until the 
cancer has progressed into advanced stages, limiting treatment options and resulting in poor prognosis. 
Patients with advanced HCC have substantially lower 5-year survival than those with early-stage disease 
(2). Given the markedly better prognosis with localized than distant disease, screening for early stage 
disease may offer the opportunity to improve the clinical management of HCC.
The major risk factors of HCC are chronic infections with hepatitis B or hepatitis C virus (HBV or 
HCV respectively). Chronic hepatitis can progress into cirrhosis (severe scarring or ﬁ  brosis of the liver), 
which increases the risk of developing HCC (3). Patients with chronic hepatitis and/or cirrhosis there-
fore form a high risk population which would beneﬁ  t from regular screening for HCC by serial mea-
surement of serum alpha-fetoprotein (AFP) levels and hepatic ultrasound (4, 5). AFP is a fetal 
glycoprotein produced by the yolk sac and fetal liver. Its serum levels usually decrease immediately 
after birth and then increase only in certain pathologic conditions, including HCC (4, 6). Elevated serum 
AFP (e.g. levels   20 ng/ml) is not a speciﬁ  c marker for HCC, since it is detected in a wide variety of 
non-hepatic malignancies (7–9) and benign conditions, including acute and chronic hepatitis (10–15). 
In chronic hepatitis carriers, the speciﬁ  city of AFP for HCC ranges from 80% to above 90%, but its 
positive predictive value is well below 10% (5, 16, 17). Furthermore, the sensitivity of AFP as an HCC 
marker is also limited, since 30%–50% of HCC cases do not present with elevated serum AFP (2). It is 
unclear whether the sensitivity or speciﬁ  city of AFP varies among HBV-positive, HCV-positive, and 2
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non-viral HCC (18–22); however, it is apparent 
that serum AFP fails to detect a substantial propor-
tion of HCC of any etiology.
The sensitivity of ultrasound imaging for detec-
tion of HCC tumor nodules is also limited, ranging 
from 35% to 81% and varying by operator and 
hospital (23). Moreover, because lesions identiﬁ  ed 
with ultrasound are frequently re-examined by 
computed tomography (CT) scan, the cost of radio-
graphic tests for HCC is high (3). Even with heli-
cal CT, approximately 30% of tumors smaller than 
2 cm may escape detection (23), again limiting the 
utility of radiographic screening for early HCC. 
Therefore, screening methods with improved sen-
sitivity and speciﬁ  city are critical to the reliable 
diagnosis of early stage HCC, which is fundamen-
tal to improving patient survival.
In this study, we used an antibody array that 
measured 75 independent serum proteins to iden-
tify potential circulating diagnostic markers of 
HCC. Because chronic hepatitis is an inﬂ  ammatory 
condition which predisposes to HCC, we used 
arrays consisting largely of antibodies against 
inﬂ  ammatory proteins to probe for those which 
may be useful for diagnosing the transition from 
hepatitis to HCC. Proteins found to signiﬁ  cantly 
differentiate HCC from hepatitis may be valuable 
as early diagnostic markers for the routine screen-
ing of patients with chronic hepatitis.
Patients and Methods
Patient samples
A total of 112 patients were recruited at Stanford 
University Hospital between April 2003 and 
August 2005. Of these, 67 patients were used to 
generate protein expression proﬁ  les using the 
antibody arrays (19 patients with chronic hepatitis 
B or C viral infections; 48 HCC patients) (Protein 
Array Group). The remaining 45 patients (22 
patients with chronic hepatitis B or C viral 
infections; 23 HCC patients) were used as an 
independent sample set for validation purposes 
(Validation Group). The patient characteristics of 
each group are shown in Table 1. Prior to blood 
draws, all patients signed informed consent 
approved by the Stanford Institutional Review 
Table 1. Patient characteristics in Protein array group and validation group.
  Protein array group  Validation group
   HCC  HBV and/or   HCC  HBV and/or 
    HCV carrier    HCV carrier
  N  (%) N (%)  N  (%)  N (%)
Age group (years)               
 50 9  (18.8)  5  (26.3)  3  (13.0)  11  (50.0)
 50 39  (81.2)  14  (73.7)  20  (87.0)  11  (50.0)
Gender                
Male 39  (81.3)  14  (73.7)  19  (82.6)  13  (59.1)
Female 9  (18.8)  5  (26.3)  4  (17.4)  9  (40.9)
Race                
Asian/Paciﬁ  c Islander  34  (70.8)  11  (57.9)  20  (87.0)  16  (72.7)
White, non-Hispanic  11  (22.9)  8  (42.1)  3  (13.0)  6  (27.3)
Other/unknown 3  (6.3)  0  (0.0)  0    0 
Hepatitis virus seropositivity                 
(HCC cases only)            
HBV-positive 26  (54.2)      17  (73.9)   
HCV-positive 10  (20.8)      4  (17.4)   
HBV- and HCV-positive  1  (2.1)      1  (4.3)   
None/unknown 11  (22.9)      1  (4.3)   
Peak alpha-fetoprotein                 
(ng/ml)            
 20 18  (37.5)  17  (89.5)  5  (21.7)  8  (36.4)
20–199 16  (33.3)  2  (10.5)  8  (34.8)  0  (0.0)
 200 13  (27.1)  0  (0.0)  10  (43.5)  0  (0.0)
Unknown 1  (2.1)  0  (0.0)  0  (0.0)  14  (63.6)
Median  39.7     4.9     69.4     5.27   3
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Board for the use of human subjects in medical 
research. The age range of the sample population 
is 25–81 years. HCC patients were deﬁ  ned as those 
with a pathological diagnosis of HCC after surgery 
or biopsy or with an evidence of tumor on CT or 
angiography. Patients with chronic HBV or HCV 
were conﬁ  rmed to have no history of HCC and no 
radiographic evidence of tumor; they were 
followed up for at least 6 months to exclude 
individuals with asymptomatic HCC. All blood 
samples were collected in purple top Vacutainer 
tubes using EDTA as an anticoagulant, and plasma 
separated after 15 min centrifugation at 1000x g. 
Plasma samples were stored at −70°C before 
assay.
Antibody array fabrication
The antibody arrays consist of pairs of capture 
and detection antibodies against 75 unique 
proteins, including inﬂ  ammatory proteins, tumor-
speciﬁ  c proteins, and AFP (Table 2; see also 
supplemental data). The antibody pairs were 
purchased from R&D Systems, Inc. (Minneapolis, 
MN). Antibodies provided in trehalose were 
dialyzed into a trehalose-free, phosphate-buffered 
saline (PBS) solution using centrifugal ﬁ  ltration 
tubes with molecular weight cut-off of 5000 
Daltons. An Agilent inkjet-based deposition 
system (24) was used to spot the capture antibody 
solutions in quadruplicates on 1 × 3 inch chemically 
modiﬁ  ed glass substrates at two concentrations 
(250 μg/mL and 500 μg/mL), with 8 antibody 
arrays per slide. The resulting microarrays were 
sealed in a slide box and stored under nitrogen at 
room temperature. Further details of the antibody 
array manufacturing process, and characteristics 
of the arrays can be found in the Supplemental 
Data.
Antibody array processing
All binding and washing steps were perfomed at 
room temperature. The antibody arrays were 
placed in 12% non-fat milk for 10 min to remove 
unbound antibodies and to minimize non-speciﬁ  c 
adsorption. Excess milk was removed by washing 
twice in PBS with 0.05% Tween-20 (PBST), once 
in PBS (2 min each) and ﬁ  nally in distilled water 
for 1 minute. The slides were then spun dry with 
a Beckman GPKR centrifuge at 1500 rpm for 
2 min. Plasma samples were diluted three times 
with binding solution (0.4% triton X-100 and 1% 
casein block buffer (Pierce Biotechnology, 
Rockford, IL), and 40 μL of the diluted sample 
solution was applied to each chamber of the 8-
pack Gasket Slide (Agilent Technologies, Santa 
Clara, CA). Sample sets were systematically 
distributed across arrays, so that each array con-
tained samples from each of the different patient 
groups. The antibody array was then placed over 
the gasket slide, and SureHyb Gasket Chamber 
(Agilent Technologies, Santa Clara, CA) was 
assembled to seal the slides. The slides were 
incubated overnight using gentle rotation at 4 rpm 
in Hybridization Incubator (Robbins Scientiﬁ  c, 
Model 400). After incubation, the arrays were 
rinsed in PBST, washed twice in PBST (10 min 
each), once in PBS (10 min), and once in distilled 
water for 1 minute before being spun dry. Next, 
biotinylated detection antibodies were diluted 
1:90 with binding buffer (0.4% triton X-100 and 
1% casein block buffer). The detection antibody 
mixture (40 μL) was used to bind to the antigen. 
After incubation for 2 hr, the arrays were washed 
and spun dry as described above. Then 40 μL 
(0.4 μg/mL) of ﬂ  uorescent Cy3-labeled strepta-
vidin (Sigma, St. Louis, MO) was added to detect 
the signal. After 30 min incubation, the slides 
were washed and spun dry as described above. 
Finally, the arrays were scanned in an Agilent 
G2565AA DNA Microarray Scanner (Agilent 
Technologies, Santa Clara, CA) at 100%, 10%, 
and 2% PMT individually using 5 μm resolution 
with only the green channel on. Each sample was 
measured on two separate slides to check for 
reproducibility. To assess background levels of 
nonspeciﬁ  c antibody binding to the arrays, eight 
“blank” arrays with buffer in the place of plasma 
were processed together with the other samples. 
Further measurements of background signal and 
antibody cross reactivity are presented in the 
Supplemental Data.
Data Extraction
The location of each antibody spot on the array 
was outlined using Agilent Feature Extraction 
software version A.7.5.1 (Agilent Technologies, 
Santa Clara, CA). The signals for each spot were 
obtained by subtracting the median of pixel 
intensities from the local area around each spot 
from the average pixel intensity within each spot. 
The array elements for which the ﬂ  uorescent 
intensity of each spot was less than 3 times the 4
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Table 2. List of antibodies included on arrays.
Gene symbol  Gene name  Biological process
ADIPOQ  Adiponectin  Metabolic and hormonal processes, 
   phosphate  transport
AFP Alpha-fetoprotein  Immune  response,  transport
BCL2 B-cell  CLL/lymphoma  2  Anti-apoptosis
BAX BCL2-associated  X  protein  Apoptosis
CCL1  Chemokine (C-C motif) ligand 1  Calcium ion homeostasis, cell-cell 
   signaling
CCL11  Chemokine (C-C motif) ligand 11  Calcium ion homeostasis, cell-cell 
   signaling,  cell  adhesion
CCL13  Chemokine (C-C motif) ligand 13  Calcium ion homeostasis, cell-cell 
   signaling
CCL18  Chemokine (C-C motif) ligand 18  Antimicrobial humoral response, cell-cell 
   signaling
CCL2  Chemokine (C-C motif) ligand 2  G-protein signaling, anti-apoptosis, cell 
   adhesion
CCL21  Chemokine (C-C motif) ligand 21  Cell-cell signaling, chemokine activity
CCL22  Chemokine (C-C motif) ligand 22  Antimicrobial humoral response, cell-cell 
    signaling, chemokine response
CCL28  Chemokine (C-C motif) ligand 28  Chemokine activity, chemotaxis
CCL5  Chemokine (C-C motif) ligand 5  Cell adhesion and motility, cell-cell 
    signaling, chemokine activity
CCL7  Chemokine (C-C motif) ligand 7  Antimicrobial humoral response, cell-cell 
    signaling, chemokine response
CCL8  Chemokine (C-C motif) ligand 8  Cell-cell signaling, chemokine activity
CD36  Thrombospondin receptor  Transport, cell adhesion
CDKN1A  Cyclin-dependent kinase inhibitor   Apoptosis, cell cycle arrest
 1A/p21   
CSF1  Colony stimulating factor 1 (macrophage)  Cell differentiation and proliferation
CTNNB  Beta-catenin  Wnt receptor signaling pathway, cell 
   adhesion
CX3CL1  Chemokine (C-X3-C motif) ligand 1  Cell adhesion, chemokine activity
CXCL1  Chemokine (C-X-C motif) ligand 1  G-protein coupled receptor protein 
   signaling  pathway
CXCL10  Chemokine (C-X-C motif) ligand   Cell-cell signaling, cell motility, 
 10  chemokine  activity
CXCL11  Chemokine (C-X-C motif) ligand 11  Cell-cell signaling, chemokine activity
CXCL12  Chemokine (C-X-C motif) ligand   G-protein coupled receptor protein 
  12  signaling pathway, cell adhesion, 
   chemokine  activity
CXCL14  Chemokine (C-X-C motif) ligand 14  Cell-cell signaling, chemokine activity
CXCL9  Chemokine (C-X-C motif) ligand 9  G-protein coupled receptor protein 
   signaling  pathway
EGF   Epidermal growth factor  DNA replication, activation of MAPK
EGFR  Epidermal growth factor receptor  ATP binding, cell cycle, cell proliferation
FAS  Fas  Anti-apoptosis, immune response, signal 
   transduction
FASLG Fas  ligand  Apoptosis
FGF2  Fibroblast growth factor 2 (basic)  Ras protein signal transduction, 
    angiogenesis, cell differentiation and 
   proliferation
HGF  Hepatocyte growth factor  Growth factor activity
IGF1  Insulin-like growth factor   DNA replication, Ras protein signal 
   transduction
IGFBP1  Insulin-like growth factor   Cell growth, signal transduction
 binding  protein  1
IGFBP3  Insulin-like growth factor  Apoptosis
 binding  protein  3
(Continued)5
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Table 2. (Continued)
Gene symbol  Gene name  Biological process
IGFBP4  Insulin-like growth factor   DNA metabolism, cell proliferation
 binding  protein  4
IGFBP6  Insulin-like growth   Regulation of cell growth
  factor binding protein 6
ICAM1  Intercellular adhesion molecule 1  Cell-cell adhesion
IFNG  Interferon, gamma  Cell motility, cell growth, immune response
IL1RN  Interleukin 1 receptor antagonist  Inﬂ  ammatory response
IL1R1  Interleukin 1 receptor, type I  Signal transduction, inﬂ  ammatory response
IL1R2  Interleukin 1 receptor, type II  Immune response
IL1B  Interleukin 1, beta  Antimicrobial humoral response, 
    apoptosis, cell proliferation
IL10  Interleukin 10  B cell differentiation and proliferation
IL12A  Interluekin 12A  T-helper cell differentiation, cytokine 
    activity, antimicrobial humoral response
IL12B  Interleukin 12B  T-helper cell differentiation, cytokine 
    activity, antimicrobial humoral response
IL13  Interleukin 13  Antimicrobial humoral response, cell 
   motility  and  proliferation
IL17A  Interleukin 17A  Apoptosis, cell-cell signaling, cytokine 
   activity
IL18  Interleukin 18  T-helper 1 type immune response, 
   angiogenesis
IL2RA  Interleukin 2 receptor, alpha  Apoptosis, cell proliferation
IL4  Interleukin 4  B cell differentiation, T-helper 2 type 
   immune  response
IL5  Interleukin 5  Cytokine acitivity, inﬂ  ammatory response
IL6  Interleukin 6  B cell differentiation, acute-phase
   response
IL6R  Interleukin 6 receptor  Cell proliferation
IL8  Interleukin 8  G-protein coupled receptor protein 
   signaling  pathway
LEP Leptin  Cell-cell  signaling
LTA  Lymphotoxin alpha  Cell-cell signaling, apoptosis, immune
   response
MIF  Macrophage migration inhibitory   Cell proliferation, inﬂ  ammatory response, 
 factor  anti-apoptosis
MMP1/TIMP1   Matrix metallopeptidase 1/Tissue   Regulation of collagen catabolism
complex  inhibitor of metallopeptidase  
 1  complex
MMP1/TIMP2   Matrix metallopeptidase 2/Tissue   Regulation of collagen catabolism
complex  inhibitor of metallopeptidase  
 2  complex
MMP10  Matrix metallopeptidase 10  Collagen catabolism
MMP2  Matrix metallopeptidase 2  Calcium ion binding, collagen catabolism
MMP9  Matrix metallopeptidase 9  Collagen catabolism
PAPPA  Pregnancy-associated plasma   Cell differentiation
  protein A, pappalysin 1 
PDGF  Platelet derived growth factor  Cell proliferation, cell-cell signaling, 
    regulation of cell cycle
RETN Resistin  Unknown
SELE  Selectin E  Cell adhesion, inﬂ  ammatory response
SELL  Selectin L  Cell adhesion and motility
TIMP1  TIMP metallopeptidase inhibitor 1  Enzyme inhibitor activity
TIMP2  TIMP metallopeptidase inhibitor 2  Enzyme inhibitor activity
TNF  Tumor necrosis factor  Regulates cell differentiation, proliferation 
    and apoptosis, cell-cell signaling, 
   inﬂ  ammatory response
(Continued)6
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standard deviation of the blank controls were 
excluded. Each antibody is represented by four 
spots on each array; if less than 2 spots were 
located by the Feature Extraction Software, the 
array element was excluded from further analysis. 
The median value was taken from the located 
spots for each antibody, and the median values 
from replicate arrays were averaged. For each 
antibody, the median of the signals from the 
blank arrays (representing background from 
antibody cross-reaction) was subtracted from 
the average intensity of each plasma sample. 
Details of the measurement and calculation of 
background signals can be found in the Supplemental 
Data. Data were log transformed before further 
analysis.
Bioinformatics Analyses
We initially identiﬁ  ed proteins that have statisti-
cally signiﬁ  cant differential expression between 
two or more groups of samples using ANOVA and 
Student’s t-test (25). Differences were considered 
statistically signiﬁ  cant if the P value was less than 
0.05. In addition to evaluating differential expres-
sion for each protein independently, we used leave 
one out cross validation analysis to identify sets of 
proteins that together can predict disease status of 
the patient (25).
Beta-Catenin Validation
by Immunoassay
Beta-catenin (CTNNB) plasma concentrations 
were determined using enzyme immunometric 
assay kits from Assay Designs, Inc. (MI, U.S.A), 
according to the manufacturer’s instructions. The 
values were log transformed, and Student’s t-test 
was used to compare the variation between two 
groups. Difference was considered statistically 
signiﬁ  cant if the P value was less than 0.05.
Results
Antibody arrays offer sensitive
and reproducible protein detection
To test the sensitivity of our antibody arrays, serial 
dilutions of standard proteins were measured. The 
sensitivity of the array varied for different antibody 
pairs, but 40% of the antibody probes tested gave 
a response with 100 pg/ml of antigen or less 
(Table 3; see also Supplemental Data). For some 
proteins which are expressed at higher levels in 
plasma, even those antibody probes with lower 
sensitivities gave robust signals (e.g. IL1RN). Each 
sample was run on duplicate arrays on different 
slides. To check the reproducibility of our array 
data, we compared the correlation between 
duplicate arrays of the same patient with the 
correlation of two random arrays (Fig. 1). The 
average r-square value of 100 duplicates was 0.98, 
while the average r-square of 100 random pairs 
was 0.90. Additionally, 76% of the duplicate arrays 
had correlation coefﬁ  cients greater than 0.99, and 
97% had correlation coefﬁ  cients greater than 0.95. 
Even duplicates in the lowest quartile of r-square 
values showed higher correlations on average than 
random pairs, indicating that platform variation 
was less than biological variation. Additional 
information describing the antibody array platform 
can be found in the Supplemental Data section.
HCC can be signiﬁ  cantly
differentiated from chronic hepatitis
We used supervised learning methods to identify 
the proteins most highly variable between the 
two groups. Among the 75 unique probes, 7 
showed statistically significant differential 
expression between HCC (n = 49) and hepatitis 
(HBV or HCV; n = 18) groups: AFP, beta-catenin 
(CTNNB), and colony stimulating factor-1 
Table 2. (Continued)
Gene symbol  Gene name  Biological process
TNFRSF11B  Tumor necrosis factor receptor   Apoptosis, cytokine activity
  superfamily, member 11b 
TNFRSF1A  Tumor necrosis factor receptor   Apoptosis, enzyme binding
  superfamily, member 1A 
VCAM1  Vascular cell adhesion molecule 1  Cell-cell adhesion
   inﬂ  ammatory response
VEGF  Vascular endothelial growth factor  Angiogenesis7
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(CSF1) were up-regulated in HCC; L-Selectin 
(SELL), insulin growth factor binding protein-6 
(IGFBP6), interleukin 6 receptor (IL6R), and 
vascular cell adhesion molecule 1 (VCAM1) 
were very slightly down-regulated in HCC 
(p   0.05) (Table 4, Fig. 2).
Although these proteins were expressed 
differentially between the HCC versus hepatitis 
groups, each by itself was not a perfect classiﬁ  er 
for the prediction of HCC, and the magnitude of 
the differences was often low. However, the 
combined pattern of four proteins, AFP, SELL, 
IGFBP6, and IL6R, can create a high quality 
predictor. The robustness of the classiﬁ  er to separate 
the two groups was investigated using a weighted-
voting algorithm and evaluated by cross validation 
testing (25). A positive predictive value of 78% (55 
out of 71 correct classifications) for the study 
population was obtained.
HCCs with AFP  20 ng/ml can be 
signiﬁ  cantly differentiated from 
chronic hepatitis
Among the 75 unique probes, 8 showed statistically 
signiﬁ  cant differential expression between speci-
mens from HCC patients with ‘normal’ serum AFP 
 20 ng/ml (n = 16) and specimens from hepatitis 
patients (with HBV or HCV infections) (n = 18): 
interleukin-1 receptor antagonist (IL1RN), inter-
feron-gamma (IFNG), cyclin-dependent kinase 
inhibitor 1A (CDKN1A), resistin (RETN), chemo-
kine (C-X-C motif) ligand 14 (CXCL14), and 
CTNNB were up-regulated in HCC with low AFP, 
whereas ﬁ  brolast growth factor-basic (FGF2), and 
SELL were down-regulated in HCC with low AFP 
(p   0.05) (Table 5, Fig. 3).
A classiﬁ  er made from two proteins, CDKN1A 
and tumor necrosis factor-beta (TNFB), was cre-
ated using the forward search method. A positive 
predictive value of 80% (27 correct classiﬁ  cations 
out of 34) was achieved by cross validation. TNFB 
by itself was not a signiﬁ  cant distinguisher between 
these two groups of patients (p = 0.073).
Independent Immunoassay Testing 
of a Potential Biomarker
To begin to test the robustness of the biomarkers 
we discovered on the antibody array platform, we 
used an independent immunoassay for CTNNB, 
which showed the greatest fold-change between 
HCC and hepatitis (Tables 4 and 5). We measured 
the levels of CTNNB in an ELISA which used a 
different antibody pair than those on the array 
(further examples of ELISA/array comparisons are 
shown in Supplemental Data). Specimens from 
HCC patients (n = 42) and from hepatitis patients 
Table 3. Antigen titration data. Data for a subset of the 
antibody probes on the array is shown.  Sensitivity was 
tested by applying dilutions of pure antigens in PBS 
buffer and measuring the resultant ﬂ  uorescence signal 
(see Supplemental Data for sample titration curves).   
Bold indicate the approximate limit of detection for that 
protein, meaning that lower antigen levels were not 
detected.  Other numbers are nominal limits reﬂ  ecting 
the lowest concentration tested; the actual limit of detec-
tion for these proteins may be lower.
Probe name  L.O.D.  (pg/ml)
ADIPOQ 25
CCL1 200
CCL13 1400
CCL18 5000
CCL22 280
CCL28 240
CCL5 170
CCL7 20
CCL8 400
CSF1 400
CXCL10 160
CXCL11 25
CXCL9 5000
FAS 69
FASLG 22
IGFBP1 19
IGFBP4 4000
IL1B 3
IL1RN 1400
IL1R2 188
IL1R1 100
IL10 840
IL12A 268
IL18 75
IL2RA 39
IL4 100
IL5 11
IL6 200
IL6R 36
IL8 266
LTA 200
MIF 240
MMP10 200
MMP9 650
RETN 19
SELE 750
TNF 4100
TNFRSF11B 71
VCAM1 108
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(n = 15) were randomly selected from the Protein 
Array Group, and their CTNNB levels were mea-
sured using commercially available ELISA kits 
from Assay Designs, Inc. Although correlation of 
immunoassay results with that of antibody array 
results was poor (R
2 = 0.375), the expression level 
of CTNNB in HCC (median = 651 pg/ml) was 
signiﬁ  cantly higher than that in the hepatitis group 
(median = 575 pg/ml) (p = 0.025) (Fig. 4A). 
Additionally, when comparing 16 HCC patients 
with low AFP (AFP  20 ng/ml) to 15 patients with 
chronic hepatitis, CTNNB remains signiﬁ  cantly 
elevated in the group of HCC patients with AFP 
 20 ng/ml (median = 1307 pg/ml) (p = 0.036) 
(Fig. 4B). We found similar results in the Validation 
Group: CTNNB was signiﬁ  cantly more abundant 
in 23 HCC patients (median = 1652 pg/ml) 
compared to 22 chronic hepatitis patients 
(median = 680 pg/ml) (p = 0.020) (Fig.  4C). However, 
because of small sample numbers, the comparison 
of CTNNB levels between HCC patients with AFP 
 20 ng/ml and hepatitis patients (n = 6) only 
approaches significance (p = 0.07) (data not 
shown).
Although the magnitudes of the ELISA signals 
only show a weak correlation to the array signals, 
the results are consistent with our antibody array 
data, implying that beta-catenin may be a potential 
diagnostic marker for HCC, including HCC with 
undiagnostic levels of AFP.
Discussion
Using an antibody array technology, we identiﬁ  ed 
circulating markers that distinguished HCC 
patients from patients with chronic hepatitis. 
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Figure 1. Duplicate arrays show greater correlation coefﬁ  cients than a random pair of arrays. Background-subtracted log-10-transformed 
ﬂ  uorescence signals for each protein are shown with one sample shown on each axis. The tight distribution of data in the duplicate arrays 
indicates the platform reproducibility.9
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We used an independent immunoassay method to 
conﬁ  rm that one of the markers, CTNNB, shows 
differential expression when measured with anti-
bodies from a different supplier. The protein mark-
ers that we identified have little or no prior 
association with HCC, and are thus novel candi-
dates as diagnostic markers for HCC. Importantly, 
some of these markers (e.g. CTNNB) could poten-
tially be useful for detecting HCC in patients with 
lower than diagnostic levels of AFP.
The antibody array that we used includes 
antibodies against proteins involved in inﬂ  ammation 
(such as cytokines, chemokines, interleukins, 
interferons); proteins involved in cell adhesion and 
the extracellular matrix; proteins involved in 
apoptosis; growth factors and their receptors and 
binding proteins, and AFP. Since chronic hepatitis 
infection is the major risk factor for the development 
of HCC, inﬂ  ammatory proteins might be expected 
to be elevated in the early transition from hepatitis 
to HCC, and their over-abundance in HCC might 
be useful diagnostic indicators for this hard-to-detect 
malignancy. Whereas some of these inﬂ  ammatory 
proteins might indeed have some causative roles 
in the development of HCC, others might be 
indicators of the host response to the infection or 
tumor. Clearly, the multivariate analysis enabled 
by antibody arrays offers better power than 
individual measurements for classifying the 
samples, irrespective of whether the mechanism 
of the individual proteins in HCC is known.
Our identiﬁ  cation of AFP as a marker that is 
over-expressed in HCC conﬁ  rms the robustness of 
our technology and bioinformatics analyses. 
Among 8 potential markers of HCC, only AFP and 
CTNNB are more than twofold more abundant in 
HCC compared to hepatitis. While the magnitude 
of the expression differences was low for the other 
potential markers, the low p-values indicate that 
the small changes may be signiﬁ  cant when detected 
on a platform with low noise. Although SELL most 
significantly distinguishes HCC patients from 
hepatitis patients, it is less abundant in HCC. 
Intuitively, proteins that are under-expressed in 
HCC compared to hepatitis appear to have less 
clinical value than those that are over-expressed in 
HCC. However, this does not negate their potential 
clinical utility as diagnostic and therapeutic mark-
ers, given that other established diagnostic or 
prognostic tests are based on low marker levels 
(e.g. CD4+ T-cell count, white blood cell count, or 
thyroid hormone concentration). It is also 
conceivable that a panel of markers, some of which 
are up-regulated and some of which are down-
regulated in HCC, might have greater diagnostic 
value than a single marker alone.
Table 4. Top scoring proteins that significantly 
differentiate HCC from hepatitis.
Probe  t-test score   Ratio fold change
 p  value  (HCC/hepatitis)
1. AFP  0.003  2.40
2. CTNNB  0.031  3.51
3. CSF1  0.036  1.46
4. SELL  0.002  −1.21
5. IGFBP6  0.014  −1.15
6. IL6R  0.020  −1.10
7. VCAM1  0.046  −1.07
HBV + HCV
VCAM1
IL6R
IGFBP6
SELL
CSF1
CTNNB
AFP
HCC
1
2
3
4
5
6
7
Figure 2. Heatmap for top scoring proteins that differentiate between HCC and hepatitis. The yellow shade represents higher ﬂ  uores-
cence signals for the protein and blue shade represents the lower signals for the proteins. AFP, CTNNB and CSF1 show up-regulation in 
HCC group, while SELL, IGFBP6, IL6R and VCAM1 show down-regulation in HCC group.10
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CTNNB and SELL appear to have the potential 
to distinguish not only HCC patients from hepati-
tis patients, but also HCC patients with AFP  20 
ng/ml from hepatitis patients. Proteins that uniquely 
distinguish HCC patients with low AFP from 
patients with hepatitis include IL1RN, IFNG, 
CDKN1A, RETN, CXCL14, and FGF2. These 
protein markers have potentially important clinical 
impact in the detection of HCC patients that are 
undiagnosed due to their low levels of AFP.
CTNNB stands out as a promising marker for 
HCC, as well as for HCC with low AFP, since it 
shows at least 3 fold abundance over patients with 
chronic hepatitis. Furthermore, its significant 
over-abundance in both groups of HCC patients 
was validated by independent immunoassay 
method. CTNNB is an adherent junction protein 
that helps to mediate adhesion between cells, and 
to maintain epithelial layers such as those lining 
organ surfaces (http://genome-www5.stanford.
edu/cgi-bin/source/sourceSearch). Tumor cell 
metastasis, which involves the disruption and re-
establishment of epithelial cell-cell contacts, may 
be regulated by the disassembly and assembly of 
adherent junctions. Activating mutations in CTNNB 
have oncogenic activity and have been found in 
various types of tumors, such as colon, ovarian, 
prostate, and liver. CTNNB also regulates signal 
transduction through the Wnt pathway, which is 
known to be dysregulated in various types of 
cancers, including HCC and melanoma (26, 27).
The expression of CTNNB in HCC has been 
detected immunohistochemically by several 
groups. Mutated nuclear CTNNB over-expression 
has been associated with increased cell prolifera-
tion (28) and poorer survival (29). Non-nuclear 
types of CTNNB over-expression (in the cytoplasm 
and/or cytoplasmic membrane) may also have 
pathologic and prognostic significance, being 
associated with tumor size  5 cm, poorer cellular 
differentiation, and shorter disease-free survival 
(30). However, there has been no report of serum 
detection of CTNNB in HCC, nor of its associa-
tions with clinicopathological features of HCC. 
Given the important biological implications of 
CTNNB in HCC, the ability to detect it in periph-
eral blood of HCC patients would offer a valuable, 
non-invasive way of HCC diagnosis and prognos-
tication. Our data further suggests that CTNNB 
Table 5. Top scoring proteins that signiﬁ  cantly differen-
tiate HCC with AFP  20 ng/ml from hepatitis.
Probe  t-test score   Ratio fold change 
 p  value  (HCC/hepatitis)
1. IL1RN  0.006  1.96
2. IFNG  0.009  1.80
3. CDKN1A  0.019  1.67
4. RETN  0.019  1.85
5. CXCL14  0.022  1.65
6. CTNNB  0.026  3.91
7. FGF2  0.021  −3.61
8. SELL  0.039  −1.19
HBV + HCV
FGF2
RETN
IL1RN
IFNG
CDKN1A
SELL
Tissues
CXCL14
CTNNB
HCC,AFP<20 ng/ml 
1
2
3
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Figure 3. Heatmap for top scoring proteins that differentiate between HCC with AFP  20 ng/ml and hepatitis. The yellow shade 
represents higher ﬂ  uorescence signals for the protein and blue shade represents the lower signals for the proteins. IL1RN, IFNG, CDKN1A, 
RETN, CXCL14 and CTNNB show up-regulation in HCC group with normal AFP level ( 20 ng/ml). FGF2 and SELL show down-regulation 
in HCC group with normal AFP level ( 20 ng/ml).11
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Figure 4. Box plots showing the distribution of measurements of CTNNB serum levels by an independent immunoassay. The median 
values are indicated by triangles, the minimum and maximum values are squares and crosses, respectively, and the box deﬁ  nes the boundaries 
of the ﬁ  rst and third quartiles of data. Sample groups are on the x axis and the logarithm of the measured protein concentration is on the y 
axis. (A). Samples (42 HCC and 15 hepatitis patients) were randomly selected from the Protein Array Group, and CTNNB levels measured 
to be statistically signiﬁ  cant between the 2 groups (p = 0.025). (B). Among these samples, CTNNB levels were also statistically signiﬁ  cant 
between HCC patients with AFP  20 ng/ml (n = 16) and hepatitis patients (n = 15) (p = 0.036). (C). Signiﬁ  cant differential levels of CTNNB 
were conﬁ  rmed in an independent Validation Group consisting of 23 HCC and 22 hepatitis patients.12
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could be a useful complementary marker to AFP 
in the diagnosis of HCC.
Our current study is the ﬁ  rst of many steps in 
the identiﬁ  cation of novel diagnostic markers for 
HCC (31). Pending validation of these results by 
immunoassays in an independent set of samples, 
each potential marker needs to undergo further 
evaluation steps as outlined below (32): 1). a 
“preliminary performance” study comparing the 
performance of the marker between subjects with 
and without symptomatic cancer; 2). a “retrospective 
performance” study evaluating the performance of 
the marker in stored, pre-disease specimens from 
asymptomatic subjects who went on to develop 
cancer, compared to those who did not; 3). a 
“prospective performance” study evaluating the 
performance of the marker in a follow-up cohort of 
asymptomatic subjects, comparing those who are 
later diagnosed with cancer to those who are not; 
and 4). a “cancer screening” study, ideally in the 
form of a randomized clinical trial, evaluating the 
clinical utility, beneﬁ  ts, and harms of the marker as 
the basis for early intervention (31, 32).
In conclusion, we used arrays of antibodies 
against inflammatory proteins to identify novel 
potential circulating markers of HCC. Importantly, 
several of these markers are elevated in HCC patients 
with non-elevated AFP, and therefore, may be used 
clinically to complement the current AFP diagnostic 
test for more accurate detection of HCC. The clinical 
value of these markers, and especially of beta-
catenin, warrants further large scale validation.
Note
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I. Details of antibody array manufacturing
The Agilent deposition system is comprised of an engineered print head that can hold sixty different 
solutions and dispense ~40 picoliters per spot. The precision and accuracy of liquid dispensing is com-
puter controlled. The printing was performed on 12 × 12 inch glass wafers which were then diced into 
1 × 3 inch slides. The system prints multiple wafers with the same load of antibody solutions. The 
content can be composed of antibodies, full-length proteins, protein fragments; further details of the 
system can be found in reference 24 of the paper. In our study, we printed antibodies on an Agilent 
proprietary chemically modiﬁ  ed surface. The antibodies adsorbed to the surface via non-covalent inter-
actions. We designed the arrays such that one 1 × 3 inch slides holds 8 identical arrays for 8 samples 
or controls (Fig. S1). Each antibody was printed in four replicates at two different concentrations per 
array for statistical calculations. Samples for the array can range from discrete proteins to complex 
biological matrices such as serum or cell lysates. The array was processed under the protocol described 
in the paper using Agilent Sure Hyb chambers and 8-pack gaskets.
II. Background signal and antibody cross-reactivity
As the number of antibodies increases, the potential for antibody or antigen cross-reactivity also rises. 
We addressed this by doing extensive quality control experiments for each new antigen and antibody 
pair that was added to the arrays; antigen/antibody sets which led to a signiﬁ  cant increase in signal in 
the absence of antigen were left off of the array and out of the detection antibody mixture. Furthermore, 
for each experiment we measured the feature background signal with a “blank” array which had only 
buffer and detection antibodies applied; if the detection antibody mixture showed signiﬁ  cant ﬂ  uorescent 
signal in the absence of sample, it was likely that some detection antibodies in the mixtures were binding 
directly to the capture antibody spots. The substrate background signals from proteins binding where 
no capture antibody was printed were consistently very low (30–60) and were not included in further 
calculations. The feature background signals and actual sample signals were different for each antibody 
pair, and thus the background-subtracted signal was calculated independently for each antibody pair 
(see methods). In general we found that the feature background signals increased as the number of 
antibodies in the detection mixture increased (Fig. S2 A), but we found the feature background signals 
to be manageable with careful selection of antibody reagents. Also, we performed an independent 
experiment using the same sample with mixtures of either 40 or 60 detection antibodies, and measured 
the increase in signal in the buffer blank and sample arrays. We found that the extra 20 antibodies into 
the mixture only increased the median background signal by 300, while the signiﬁ  cant signals from 
plasma samples were usually in the range of 5000–200000 (Fig. S2 B). Finally, because the actual levels 
of antigen could be very low in many samples, a failure to detect signal above background does not 
mean that the antibody pair is not working.
We further quantitated the level of cross-reactivity by measuring speciﬁ  c and nonspeciﬁ  c signals 
during antigen titrations (data not shown). While we usually saw a large, linear increase in ﬂ  uorescence 
at the array feature for the speciﬁ  c antibody (Fig. S4), there was rarely any signiﬁ  cant increase in signal 
in the nonspeciﬁ  c features.15
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III. Protein array sensitivity—Antigen titration curves and comparison to ELISA 
results
Once the array was printed, each antibody was tested for its response in terms of ﬂ  uorescent signal as 
a function of speciﬁ  c antigen concentration in order to determine the sensitivity and dynamic range of 
array (Fig. S3). More limit of detection (LOD) data can be found in Table 2. The array performance 
was evaluated against ELISA using the same capture antibody and biotinylated detection antibody pair 
(Fig. S4 and S5). In general, the array provided similar LOD as ELISA if not better, but with much 
broader dynamic range.
Figure S1. Agilent 8-pack antibody array. A scanned ﬂ  uorescent image of 8 protein arrays on one slide is shown; one array is enlarged 
to show detail. On a typical array, background signals in between the antibody features ranged from 30–60 ﬂ  uorescent units, while the 
signals on the antibody features ranged from 200–400000.16
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Figure S2. Distributions of signals from samples versus background signals with different levels of multiplexing. A. Histograms of 
the signal distributions from buffer blanks using four different detection antibody mixtures are shown. As the number of antibodies in the 
detection mixture increased, the background ﬂ  uorescence in the array features increased, but the peak of the distribution remained  1500. 
B. Histograms of signals from all sample arrays for the four different detection antibody mixtures are shown with the same scale as A. For 
data analysis, we calculated signiﬁ  cant background-subtracted signals using three standard deviations of the blank signal for each antibody. 
However, it is clear from these plots that very few antibodies had ﬂ  uorescence signals  5000 in the absence of samples, while many high 
signals were measured when actual samples were applied.
A.  Distribution of background signals
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B. Distribution of sample signals
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Figure S3. Examples of Antigen titrations. Puriﬁ  ed antigen proteins in buffer were applied to protein arrays, and the relative ﬂ  uorescent 
signal was measured. Many proteins showed approximate limits of detection (LOD)  100 pg/ml.
Figure S4. Limit of detection for ELISA versus protein array. LODs were measured with puriﬁ  ed antigen titrations on the two platforms, 
using ELISA kits constructed with the same antibody pairs used on the protein array.
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Figure S5. ELISA versus protein array results for the protein Leptin. Relative ﬂ  uorescent signals from ELISA and the protein array are 
plotted. The ELISA kit used the same antibody pairs as the protein array.